Accellix is a pioneering brand that is revolutionizing the field of quality control in the cell and gene therapy industry. Their next-generation analytical capabilities allow for the measurement of critical quality attributes at every QC phenotyping interrogation point throughout the manufacturing process. This ensures the release of cell therapy products precisely when and where they are needed.

Accellix's flagship product is the Accellix Platform, a compact and automated cell phenotyping platform designed specifically for point-of-need environments. This platform integrates seamlessly into both centralized and de-centralized models, simplifying and standardizing the cellular analysis process. It covers everything from sample preparation to data analysis, eliminating the need for separate lab spaces, skilled technicians, and long turnaround times.

Their team consists of experts in cell therapy, including biologists, engineers, mathematicians, and technicians. They bring extensive experience to the table, ensuring the highest quality of products and services. Overall, Accellix aims to accelerate and elevate their customers' ability to save lives with their transformative therapies.

By providing quick and accurate flow cytometry capabilities, they enable their partners to measure critical quality parameters and deliver life-saving treatments to patients faster than ever before